Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Episodes
72 episodes
Final Episode
This week, I have an announcement to make. Find out more athttps://LifeScienceTodayPodcast.com
•
Season 3
•
Episode 124
•
4:35
Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago
Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyoutFind out more athttps://LifeScienceTodayPodcast.comStory Refer...
•
Season 3
•
Episode 123
•
8:47
Indivior + Opiant, Regeneron + CytomX, Rezo, Provention
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvalsFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 122
•
6:07
Intellia, Regeneron, Viatris + Oyster Point
More CRISPR data, oncology wins, and a new player in ophthalmologyFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 121
•
9:41
Sumitovant + Myovant, Thermo Fisher + Binding Site Group, Astellas & Taysha, Agios, Vaxctye
Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for othersFind out more athttps://LifeScienceTodayPodcast.comStory Refere...
•
Season 3
•
Episode 120
•
8:35
FDA, AbbVie + DJS, Roche + Hookipa, Kyverna
Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future. Find out more athttps://LifeScienceTodayPodcast.comStory R...
•
Season 3
•
Episode 119
•
8:26
DICE, Odyssey, Fred Hutch, Merck (MSD)
One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news Find out more athttps://LifeScienceTodayPodcast.com
•
Season 3
•
Episode 118
•
7:23
Nested, Cellarity, Replimune, Estrella
Biotech’s with a series A, a series C, some debt financing, and there is even a Biopharma heading for a SPACFind out more athttps://LifeScienceTodayPodcast.comStor...
•
6:59
Eisai + Biogen, Amylyx, Sanofi + Regeneron
Major Alzheimer’s news, an ALS approval, and expanded therapies for skin conditionsFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 116
•
7:31
Alnylam, Intellia, Third Harmonic, Galvanize
A $900 raise, gene therapy news, a quick IPO, and merge three for $100MFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 115
•
8:06
Revance, Velocity + MedPharmics, Arsenal, SpringWorks
A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company. Find out more athttps://LifeScienceTodayPodcast.com...
•
Season 3
•
Episode 114
•
8:49
Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus
A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines. Find out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 113
•
6:49
Alcon + Aerie, Novartis + Sandoz, Labcorp + RWJBH
Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related. Find out more athttps://LifeScienceTodayPodcast.com...
•
Season 3
•
Episode 112
•
6:18
Bluebird, Endo & Pharmacies, Genentech + Jemincare, Merck + Orna
Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership. Find out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 111
•
8:33
Pfizer, Cerevel, Abbott, AstraZeneca + Daiichi Sankyo
Spending that COVID money, brain money, Irish money, and another oncology approval. Find out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 110
•
6:43
Zymergen + Ginkgo, Cassava, Teva
This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives? Find out more at
•
Season 3
•
Episode 109
•
7:18
ZyVersa, Incyte, Revolution, Frontera, CAMP4, ForSight, Auron
There’s a SPAC, expanded FDA approval, more of the common, and two Bs, two AsFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 108
•
8:06
Vertex + ViaCyte, Theravance, Merck + Orion, Pliant, Qiming
Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital Find out more athttps://LifeScienceTodayPodcast.comStor...
•
Season 3
•
Episode 107
•
7:08
Feed Drop - Interview with Dan Agroskin
FEED DROP - Clinical Research Evolved Noah and John talk with Dan Agroskin, a managing director at a leading private equity firm with a focus on the clinical research industry. We discuss how investments shape industries, what en...
•
Season 3
•
Episode 106
•
37:11
Galapagos + CellPoint + AboundBio, Radius, Ipsen + Epizyme, DEM Bio
Double acquisition, private money, affordable deals, and a surprising $70M launchFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 105
•
6:49
AbbVie, Third Rock, Scholar Rock, Kyowa Kirin
Crohn’s approval, new VC round, direct offerings, and potential asset sales. Find out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 104
•
5:50
Bluebird, FDA, Resilience, Corvia, Code, Mineralys, Tessa
Gene therapy, minor legislation, a $625M series D, and four companies raise $373M.Find out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 103
•
8:25
GSK + Affinivax, Pfizer – Haleon, Regeneron, Roche + Repare
Pharma buys, pharma splits, pharma trades, and oncology biobucks from pharmaFind out more athttps://LifeScienceTodayPodcast.comStory References
•
Season 3
•
Episode 102
•
6:05